PHARMACY MARKET, PHARMA TECH
prnewswire | April 18, 2023
Science and technology company Merck and XtalPi Inc., a pioneering pharmaceutical technology company powered by artificial intelligence (AI) and automation, have jointly published a study that highlights the benefits of combining computational workflows with wet lab experiments to advance drug development.
Traditional methods like milling and micronization, used to address undesirable crystal morphologies, can be disruptive and costly. In contrast, molecular dynamics simulations offer valuable insights for better crystallization experiment designs.
The collaboration between Merck and XtalPi focused on the impact of different polymer additives on the crystal habit of metformin HCl, a diabetes medication. By combining Merck's experimental capabilities with XtalPi's morphology prediction platform, a comprehensive screening approach for crystal morphology engineering was developed. XtalPi's custom-made force fields successfully predicted the influence of polymer additives on metformin HCl's crystal habits. The addition of HPMC led to a transformation from a needle-like to a prismatic morphology, in agreement with experimental observations. The publication demonstrates the potential of merging computational methods and experimental expertise for drug formulation optimization.
Dr. Peiyu Zhang, XtalPi's Chief Scientific Officer, said, "By integrating XtalPi's molecular dynamics predictions with Merck's experimental validation, we have taken a step towards the rational engineering of desirable crystal habits. We hope to continue improving this 'dry + wet lab' method with leading industry experts like Merck, in the production of novel therapeutics worldwide."
Dr. Jan Gerit Brandenburg, Head of Digital Chemistry at Merck, added, "Our collaboration with XtalPi is transforming pharmaceutical development. By seamlessly incorporating computer simulations with our experimental formulation expertise in a 'digital-first' approach, we are boosting drug development processes and positively impacting patients' lives."
About XtalPi
XtalPi is a quantum physics and AI-powered pharmaceutical technology platform that provides integrated drug discovery solutions for global pharmaceutical companies. XtalPi has pioneered a new model for drug R&D that leverages a tightly interwoven trifecta of AI, autonomous labs, and expert domain knowledge. The company applies this three-pronged approach in its R&D platform to accelerate the drug discovery and development process and address unmet needs for patients worldwide.
Read More
BUSINESS INSIGHTS, PHARMACY MARKET
Prnewswire | April 25, 2023
On April 20, Patsnap, the world's leading SaaS provider for intelligence, announced the launch of its latest version of the intelligence platform, Synapse, available to visitors. This version includes advanced search functions for drugs and pharmaceutical organizations, now publicly accessible for the first time. Users can explore these features without prior registration, making searching easier and more accessible than ever before.
Synapse is an innovative Life Sciences Platform that uses AI technology to connect Drug Discovery information with Drug Development insights. This allows professionals in the pharmaceutical industry to make better-informed decisions throughout the entire innovation cycle. With a vast database of millions of free data points from over 150 jurisdictions, Synapse provides access to over 72,000 new drugs, 800,000 clinical trials, 6 million pharmaceutical patents, 62 million literature sources, 360,000 pharmaceutical organizations, and more. This wealth of information is available to users to aid them in their research and decision-making processes.
One of the key benefits of Synapse is its extensive database of drugs, particularly those in their preclinical or early developmental stages, which helps to mitigate potential risks for professionals in the pharmaceutical industry. "We want to ensure that we are only developing drugs that are efficiently managed, reducing the risks of failure at the later stages of development," said one of our key clients, the head of R&D. By having access to this valuable information, professionals can make more informed decisions and focus their efforts on drugs with a higher potential for success, ultimately saving time and resources.
Available on Synapse's website as a free solution, key features include
Drug Advanced Search:Quickly and accurately identify drugs based on specific criteria of interest. The search function covers global drug candidates and marketed drugs, and mines preclinical R&D intelligence in patents and literature to identify early competitive risks.
Clinical Progress:Screen clinical trials by drugs, institutions, targets (multi-target), indications, clinical trial phase, and other conditions. Synapse collates data from 18 registries, including CT.gov and WHO, giving users a global view of the clinical landscape.
Playbook: Access multiple data sets with a single search, including Due Diligence and Find Organizations. This feature provides comprehensive and visualized insights into the organization's R&D preferences, drug pipeline, investments, financing, and more.
Literature Search:With over 62 million literature records in the life sciences field, users can easily screen literature by drugs, targets, indications, authors, and other criteria. This feature allows for efficient and targeted research, saving time and increasing productivity.
About Patsnap
Founded in 2007, Patsnap is the company behind the world's leading AI-powered innovation intelligence platform. Patsnap provides global businesses with a connected, easy-to-use platform that helps them make better decisions in the innovation process. Customers are innovators across multiple industry sectors, including agriculture and chemicals, consumer goods, food and beverage, life sciences, automotive, oil and gas, professional services, aviation and aerospace, and education.
Read More
BUSINESS INSIGHTS, PHARMACY MARKET
Businesswire | May 10, 2023
AustinPx, a contract development and manufacturing organization (CDMO) specializing in analytical and formulation development services and cGMP manufacturing for small molecule drugs, today announced the expansion of its capabilities to meet industry demand for the Company’s services and expertise. The Company has added new spray drying and encapsulation capabilities and has also expanded its GMP manufacturing capacity for high shear and fluid bed granulation.
AustinPx has installed and validated a Dott. Bonapace INCAP capsule filler, a Freund-Vector VFC3 model fluid bed, and a Freund-Vector GMXB-Pilot model granulator. The INCAP rounds out the Company’s solid dose manufacturing capabilities, while the fluid bed and granulator supplement the Company’s manufacturing scale.
“The investments are a key component of AustinPx’s larger strategy to expand our oral dose development and manufacturing capabilities to better serve our clients’ increasing demand,” said Justin Keen, PhD, senior vice president operations. “The additions demonstrate our ongoing commitment to providing our clients with the best possible service and support."
In line with the Company’s mission of providing science-driven formulation development, AustinPx has installed a PROCEPT modular 4M8-Trix for the development of spray dried amorphous solid dispersions. The addition supplements AustinPx’s current portfolio of bioavailability enhancement technologies, including KinetiSol® Technology - the Company’s proprietary fusion-based amorphous dispersion manufacturing platform.
“We are excited to add spray drying to our portfolio,” said Dave Miller, PhD, chief scientific officer. “When combined with our existing formulation capabilities, the addition enables us to provide a comprehensive suite of bioavailability enhancement solutions to identify the optimal formulation pathway for poorly soluble compounds and address a greater number of our clients’ challenges.”
The expanded capabilities are now available for use. These additions are the first of several strategic investments planned for the Company in the immediate future, as AustinPx continues to position itself as a leading CDMO in the pharmaceutical industry.
About AustinPx
AustinPx, Pharmaceutics and Manufacturing, is a contract development and manufacturing organization (CDMO) providing analytical and formulation development services and cGMP manufacturing for small molecule drugs. We specialize in phase-appropriate development strategies, speed to clinic and market strategies, and bioavailability enhancement of poorly soluble molecules - including our next generation amorphous dispersion platform, KinetiSol® Technology.
Read More